Remove 2027 Remove Hospitals Remove Packaging
article thumbnail

STAT+: Key House panel proposes lowering out-of-pocket drug costs in Medicare

STAT

The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.

article thumbnail

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs

STAT

The House Ways & Means Committee proposed a package that includes a new provision to ensure Medicare patients pay for medicines they pick up at pharmacies based on discounted prices insurers negotiate with drugmakers, instead of higher list prices, starting in 2027 , STAT reports. The committee has jurisdiction over Medicare.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Subcutaneous Biologics Market Analysis: Current Trends and Future Outlook

Roots Analysis

This also increases the cost of the treatment, in terms of both the cost of the prescribed therapeutic regimen and transportation / hospital cost ( due to numerous hospital visits and other healthcare costs ). Currently, antibodies segment is likely to occupy the largest share in the overall market.

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™

article thumbnail

Contamination Trends & Proposed Solutions

ISPE

The cases covered the same types of contaminants and impurities noted in Table 1: microbial contaminants, process-related im-purities, metal contaminants, packaging-related contaminants, drug cross-contamination, and an “unknown” category encompassing other contaminants associated with the manufacturing process, including those from cell culturing.